Last updated: March 21, 2026
What Is the Drug With NDC 59651-0795?
NDC 59651-0795 corresponds to Veklury (remdesivir), an antiviral medication developed by Gilead Sciences. It is primarily approved for treatment of COVID-19 in hospitalized patients.
Current Market Environment
Market Size and Adoption
- Global COVID-19 Treatment Market: Estimated to reach $34 billion by 2027, driven partly by remdesivir sales ([1]).
- Remdesivir Sales (2022): Approximately $3.2 billion, with the U.S. accounting for over 70% ([2]).
- Market Penetration: Widely adopted for inpatient COVID-19 management during the pandemic; use has declined as newer treatments emerge.
Competition and Alternatives
- Primary Competitors:
- Paxlovid (Pfizer)
- Molnupiravir (Merck)
- Regulatory Status:
- Approved or authorized in multiple jurisdictions.
- Remdesivir's initial emergency use authorization (EUA) is now supplemented by full approvals in several countries.
Market Dynamics
- Demand Trends: Peaked during 2020-2021; declining due to vaccine coverage and emergence of oral antivirals.
- Supply Chain: Gilead scaled manufacturing; supply constraints eased.
- Reimbursement and Pricing: Covered largely by government payers in the U.S., with negotiated prices around $390 per vial (average wholesale price).
Price Projections
Factors Influencing Future Pricing
- Regulatory Status
- Full approval may enable broader insurance reimbursement.
- Potential off-label and investigational uses may expand demand.
- Market Competition
- Oral antivirals may reduce hospital-based treatments' demand.
- Generic Development
- No current generic versions; patent protections remain until 2027 in the U.S.
- Manufacturing Costs
- Estimated production costs: $10–$20 per dose.
- Future price reductions may emerge from manufacturing efficiencies.
Short-Term Price Outlook (Next 1–2 Years)
| Scenario |
Assumptions |
Price Projection |
Rationale |
| Conservative |
Waning COVID-19 cases, stable demand |
$350–$400 per vial |
Limited growth due to competition and declining global cases |
| Optimistic |
New variants increase severity or demand for inpatient therapy |
$400–$450 per vial |
Increased use sustains higher prices |
| Pessimistic |
Market shifts to oral antivirals, full generic entry |
$200–$300 per vial |
Pricing pressure from generics and declining hospital use |
Long-Term Outlook (3-5 Years)
- Patent Expiry and Generics: Potential price decrease to below $200 per vial if generics enter the market.
- New Indications / Formulations: Expanded uses may sustain or increase average prices.
- Market Forces: Pricee will trend downward if competition intensifies, with estimates around $150–$250 per vial by 2028.
Strategic Considerations
- Patent Protection: Maintains pricing power until 2027 in the U.S.
- Regulatory Development: Full approval and expanded indications could influence demand and pricing.
- Market Penetration: Clinical adoption and hospital protocols will shape demand trends.
Key Takeaways
- The COVID-19 pandemic core demand for remdesivir has declined but remains relevant in specific clinical scenarios.
- The current average wholesale price is approximately $390 per vial.
- Price projections vary, with potential for significant reduction post-2027 due to patent expiry and generics.
- Competition from oral antivirals and evolving treatment guidelines will influence future sales and pricing.
- Strategic initiatives should focus on patent protection, regulatory updates, and clinical adoption to sustain value.
FAQs
1. When does Gilead's patent for remdesivir expire?
Patents in the U.S. expire in 2027, allowing for potential generic competition afterward.
2. How does remdesivir compare to oral antivirals in terms of cost?
Remdesivir price per vial averages around $390, while oral antivirals like Paxlovid cost approximately $700 per course, but are typically taken out of hospital.
3. Are there any ongoing clinical trials for new indications of remdesivir?
Yes, ongoing studies are evaluating remdesivir for cases beyond COVID-19, including other viral infections, potentially impacting future demand.
4. How has the COVID-19 pandemic affected remdesivir's market?
Initial demand surged during 2020-2021 but has since declined as vaccination rates increased and alternative treatments became available.
5. What regulatory actions could influence remdesivir's price?
Full approval, new indications, or unfavorable safety findings could alter market dynamics and pricing.
References
[1] Grand View Research. (2022). COVID-19 Treatment Market Size, Share & Trends, 2022-2027.
[2] Gilead Sciences. (2022). Annual Report 2022.
